Japan, Sept. 8 -- The Japan Bank for International Cooperation (JBIC) made an equity investment in Metagen Therapeutics, Inc. (MGTx), a Japanese startup. The investment, made through JBIC's Special Operations Account, is based on its Startup Investment Strategy. Since its foundation in 2020, MGTx has been conducting research and development of medical technologies and pharmaceuticals based on intestinal microbiome research. MGTx intends to contribute toward providing new treatments for various diseases, such as ulcerative colitis, immuno-oncology, and Parkinson's disease, in Japan and overseas, including the United States. To this end, MGTx will provide medical services to promote the social implementation of fecal microbiota transplantatio...